Indicator, Reagent, or Diagnostic Aid
Liquidia’s Yutrepia Receives Tentative FDA Approval Due to Tyvaso Exclusivity
Liquidia, Yutrepia, FDA, tentative approval, Tyvaso, exclusivity, pulmonary arterial hypertension, PAH, PH-ILD
Actinium’s Radioconjugate Faces Setback as FDA Requests New Study
Actinium Pharmaceuticals, radioconjugate, FDA, new study, Iomab-B, regulatory affairs, biotech, cancer treatment
Bristol Myers Squibb Resumes Radiopharmaceutical Phase 3 Trial Following Isotope Shortage
Bristol Myers Squibb, Radiopharmaceutical, Phase 3 Trial, Isotope Shortage, RYZ101, Actinium-225
Gan & Lee Pharmaceuticals Unveils Promising Mid-Stage Data for Homegrown Obesity Drug
Gan & Lee Pharmaceuticals, Obesity Drug, Mid-Stage Data, Clinical Trial, Weight Loss, GLP-1
Lilly Secures Option to Acquire Radionetics for $1 Billion in Radiopharma Deal
Eli Lilly, Radionetics Oncology, Radiopharmaceuticals, G Protein-Coupled Receptors, Solid Tumors, Biotechnology, Acquisition
J&J’s Tremfya Fails to Meet Primary Endpoint in Giant Cell Arteritis Trial
Tremfya, Johnson & Johnson, Giant Cell Arteritis, Phase II Trial, Primary Endpoint, Glucocorticoid-Free Remission
Jazz Pharmaceuticals’ Essential Tremor Drug Candidate Fails to Meet Primary Endpoint in Phase IIb Trial
Jazz Pharmaceuticals, suvecaltamide, essential tremor, phase IIb trial, primary endpoint, calcium channel modulator
Aerovate Therapeutics’ Shares Plummet 93.3% After Disappointing IMPAHCT Study Results for AV-101 in Pulmonary Arterial Hypertension
Aerovate Therapeutics, AV-101, IMPAHCT Study, Pulmonary Arterial Hypertension, PAH, Imatinib, Inhaled Formulation, Biotech Stocks, Clinical Trials
Telix Pharmaceuticals Aims for $200 Million IPO in Radiopharmaceuticals Market Amid Slowing Biotech Nasdaq Offerings
Telix Pharmaceuticals, Radiopharmaceuticals, IPO, Biotech, Nasdaq Offerings
ITM Secures €188 Million to Enhance Radiopharmaceutical Pipeline and Strengthen Medical Radioisotope Manufacturing
ITM Isotope Technologies Munich, radiopharmaceutical biotech, Temasek, BlackRock, Qatar Investment Authority, medical radioisotopes, Lutetium-177, Actinium-225, cancer pipeline, gastroenteropancreatic neuroendocrine tumors (GEP-NETs)